Bloomberg Businessweek
Trump’s Impossible Task
Nov 18, 2024
National correspondent Josh Green, author of 'Devil's Bargain,' delves into Trump's struggles with plutocratic populism and the challenges of maintaining a diverse voter coalition. Mike Rode, an investment director at American Century Investments, shares insights on the benefits of small-cap stocks, especially in the context of reshoring and regional banks. They discuss the implications of Trump's administration on market dynamics and the potential for small-cap growth post-election, highlighting how political shifts impact investment strategies.
41:37
Episode guests
AI Summary
AI Chapters
Episode notes
Podcast summary created with Snipd AI
Quick takeaways
- President-elect Trump's effort to blend populism with plutocracy faces challenges as the underlying economic principles do not align.
- Vertex Pharmaceuticals emphasizes collaboration and innovation across disciplines to tackle complex diseases and enhance patient treatment outcomes.
Deep dives
Vertex Pharmaceuticals' Innovative Approach
Vertex Pharmaceuticals employs a unique philosophy in its search for treatments for some of humanity's most challenging diseases. The company focuses on targeting genetic causes of diseases, which allows for the development of highly specific therapies that address the root issues rather than just managing symptoms. This approach has been pivotal in their advancements in treating conditions like cystic fibrosis, where approximately 90% of patients benefit from their targeted therapies. By harnessing cutting-edge technologies and personalized medicine, Vertex aims to provide effective solutions that significantly improve patient outcomes.
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.
